Custom service
In Vitro Immunogenicity Risk Assessment
Assess immunogenicity risk of candidates before in-vivo commitment
The service is built around MHC-II presentation prediction. Depending on the molecule we may move to T-cell activation assays (PBMC) or in-silico/ex-vivo combined scoring to improve stability, loading or yield, and every batch is released with immunogenicity risk assessment report.
Because In Vitro Immunogenicity Risk Assessment projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Candidate ranking on immunogenicity risk
Deimmunization design support
Regulatory immunogenicity conclusions without clinical data
Samples requiring containment or licensing we do not hold (BSL-3, radioactive)
Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.
Service Highlights
- MHC-II presentation prediction as the default route, with T-cell activation assays (PBMC) held as a proven fallback
- In-silico/ex-vivo combined scoring worked into the design where the application requires it
- Results are reported with detection limits and method validation status, so you know exactly what the number means
- Analytical confirmation of every intermediate before the final release
- Orthogonal methods are used by default — one measurement is an observation, two are data
- Immunogenicity risk assessment report delivered with a complete conjugation or synthesis certificate
How the work runs
Sample intake & plan
Samples are logged with chain of custody and the test matrix for In Vitro Immunogenicity Risk Assessment is confirmed.
Method selection
Analytical methods — MHC-II presentation prediction, T-cell activation assays (PBMC) — are chosen and their validation status documented.
Measurement
Testing is executed with system-suitability checks and orthogonal confirmation where required.
Data review
Chromatograms and spectra are reviewed by a second analyst before any result is issued.
Reporting
Immunogenicity risk assessment report is issued with detection limits and interpretation notes.
Follow-up support
We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.
Specifications & timeline
- Turnaround
- 5–9 weeks
- Typical scale
- µg – g sample scale
- Chemistry options
- MHC-II presentation prediction; T-cell activation assays (PBMC); in-silico/ex-vivo combined scoring
- Deliverable
- Immunogenicity risk assessment report
- QC package
- Method report, raw data, validated result with detection limits
- Shipping
- Blue ice or ambient by material; chain-of-custody on receipt
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.